Trump fast-tracks psychedelic drugs for mental healthcare use
The Trump administration signaled it will accelerate the FDA review process for psychedelic compounds like psilocybin and MDMA, targeting depression, PTSD and addiction treatment. The shift could broaden treatment options for veterans while creating opportunities for emerging biotech firms.
CNBC Top News1 h agoCOMP ATAI MNMD